Login to Your Account

Rigel, Pfizer Entering Deal For Allergic Asthma Drugs

By Randall Osborne

Friday, January 21, 2005
Rigel Pharmaceuticals Inc.'s preclinical work with IgE receptor inhibitors in respiratory mast cells to treat allergic asthma and other diseases netted the company a collaborative research and licensing deal with Pfizer Inc. - but the arrangement does not include Rigel's Phase II rhinitis drug, R112, which the big-pharma firm might scoop up later for more money. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription